https://clinicaltrials.gov/ct2/show/NCT04090229?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F07%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
DESCRIPTION:
Condition: Atopic Dermatitis
Interventions: Drug: ASLAN004; Drug: ASLAN004 Placebo
Sponsor: Aslan Pharmaceuticals
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04090229
FIRST POSTED:
Mon, 16 Sep 2019 12:00:00 EDT
LAST UPDATE POSTED:
09/21/19 11:41AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04090229?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F07%2F2019&lupd_d=14&sort=nwst
